Truist Securities Maintains Buy on Pacira BioSciences, Raises Price Target to $31
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
Truist Securities analyst Les Sulewski maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and raises the price target from $30 to $31.
Truist Securities analyst Les Sulewski maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and raises the price target from $30 to $31.